Production of Biologically Derived Small Molecule Regulatory Starting Materials and/or Active Pharmaceutical Ingredients at Commercial Scale

ASPR IBMSC through the BARDA PCI BioMaP-Consortium is seeking to develop a biological design-build-test cycle at population scale, beginning with an analytical/paper demonstration of production of small molecule drug substances at commercial scale.

This objective will support ASPR IBMSC’s broader long-term goal of developing and commercializing infrastructure that will be accessible to a broad community of users for the purpose of three biologically derived small molecule drug substances, creating a new manufacturing paradigm that can be competitive in the global market and to onshore drug production. The objective of this project is to demonstrate the ability to produce three (3) biologically derived small molecule drug substances at population scale.

You can find the solicitation on the BioMaP-Consortium website here: https://www.biomap-consortium.org/24-01-smallmol/. Submissions must be made through the BioMaP-Consortium website ONLY.